Many-body dispersions in interacting ballistic quantum wires

We have measured the collective excitation spectrum of interacting electrons in one-dimension. The experiment consists of controlling the energy and momentum of electrons tunneling between two clean and closely situated, parallel quantum wires in a GaAs/AlGaAs heterostructure while measuring the resulting conductance. We measure excitation spectra that clearly deviate from the non-interacting spectrum, attesting to the importance of Coulomb interactions. Notable is an observed 30% enhancement of the velocity of the main excitation branch relative to non-interacting electrons with the same density. In short wires, finite size effects resulting from broken translational invariance are observed. Spin - charge separation is manifested through moire patterns, reflecting different spin and charge excitation velocities.Comment: 14 pages, 6 eps figures. To be published in NANOWIRE, a special issue of Solid State Communication

Non-Leptonic Kaon Decays and the Chiral Anomaly

An investigation is performed of all non-leptonic kaon decays sensitive to the chiral anomaly. Within the framework of chiral perturbation theory, there are two classes of anomalous amplitudes at $O(p^4)$: reducible and direct contributions. Only radiative transitions are affected by the anomaly. The phenomenology of the decays $K_L \to \pi^+ \pi^- \gamma$ and $K^+ \to \pi^+ \pi^0 \gamma$ is studied in detail. Including the dominant contributions of $O(p^6)$, the experimentally observed dependence of the direct emission amplitude for $K_L \to \pi^+ \pi^- \gamma$ on the photon energy can be understood. A survey is made of the rare ``anomalous'' decays $K \to \pi \pi \gamma \gamma$ and $K \to 3 \pi \gamma (\gamma)$, including some numerical estimates.Comment: LaTeX, 31 pages (3 figures, not included), CERN-TH.6920/9

Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine

1. Behavioural and pharmacological effects of Δ9-tetrahydrocannabinol (THC) and nicotine are well known. However, the possible interactions between these two drugs of abuse remain unclear in spite of the current association of cannabis and tobacco in humans. 2. The present study was designed to analyse the consequences of nicotine administration on THC-induced acute behavioural and biochemical responses, tolerance and physical dependence. 3. Nicotine strongly facilitated hypothermia, antinociception and hypolocomotion induced by the acute administration of THC. Furthermore, the co-administration of sub-threshold doses of THC and nicotine produced an anxiolytic-like response in the light–dark box and in the open-field test as well as a significant conditioned place preference. Animals co-treated with nicotine and THC displayed an attenuation in THC tolerance and an enhancement in the somatic expression of cannabinoid antagonist-precipitated THC withdrawal. 4. THC and nicotine administration induced c-Fos expression in several brain structures. Co-administration of both compounds enhanced c-Fos expression in the shell of the nucleus accumbens, central and basolateral nucleus of the amygdala, dorso-lateral bed nucleus of the stria terminalis, cingular and piriform cortex, and paraventricular nucleus of the hypothalamus. 5. These results clearly demonstrate the existence of a functional interaction between THC and nicotine. The facilitation of THC-induced acute pharmacological and biochemical responses, tolerance and physical dependence by nicotine could play an important role in the development of addictive processes

Grand Challenges for Global Brain Sciences

The next grand challenges for society and science are in the brain sciences. A collection of 60+ scientists from around the world, together with 10+ observers from national, private, and foundations, spent two days together discussing the top challenges that we could solve as a global community in the next decade. We eventually settled on three challenges, spanning anatomy, physiology, and medicine. Addressing all three challenges requires novel computational infrastructure. The group proposed the advent of The International Brain Station (TIBS), to address these challenges, and launch brain sciences to the next level of understanding

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<l,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among postransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%. 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among parents who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patiends who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe at wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg. © 2007 AASLD

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B : final long-term results

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<1,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among posttransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, and prothrombin time normalized in 51%, 81%, 76%, and 56% of posttransplantation patients, respectively. Among wait-listed patients who underwent on-study liver transplantation, protection from graft reinfection over a median of 35 weeks was similar among patients who did (n = 34) or did not (n = 23) receive hepatitis B immunoglobulin (HBIg). Hepatitis B surface antigen was detected on the first measurement only in 6% and 9% of patients who did or did not receive HBIg, respectively. Serum HBV DNA was detected on consecutive visits in 6% and 0% of patients who did or did not receive HBIg, respectively. Treatment-related adverse events led to discontinuation of adefovir dipivoxil in 4% of patients. Cumulative probabilities of resistance were 0%, 2%, and 2% at weeks 48, 96, and 144, respectively. In conclusion, adefovir dipivoxil is effective and safe in wait-listed or posttransplantation CHB patients with lamivudine-resistant HBV and prevents graft reinfection with or without HBIg